Vanguard Global Advisers’s Atea Pharmaceuticals AVIR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$136K Buy
26,040
+359
+1% +$1.84K ﹤0.01% 2637
2026
Q2
$119K Hold
25,681
– – ﹤0.01% 2704
2026
Q1
$138K Buy
+25,681
New +$118K ﹤0.01% 2590

Other funds holding AVIR

Vanguard Global Advisers's AVIR Position: Q3 2026 in Review

Vanguard Global Advisers increased its Atea Pharmaceuticals (AVIR) stake by 1.4% in Q3 2026, buying an estimated $1.84K and bringing the position to 26,040 shares worth $136K. The position accounts for ﹤0.01% of the portfolio, ranked #2637.

Vanguard Global Advisers first reported a position in AVIR in Q1 2026 and has held it in 3 quarters since. The position peaked at $138K in Q1 2026. 127 funds tracked by Wall St. Rank hold AVIR as of Q3 2026.

  • Vanguard Global Advisers held 26,040 shares of Atea Pharmaceuticals worth $136K as of Q3 2026.
  • Vanguard Global Advisers bought 359 Atea Pharmaceuticals shares in Q3 2026, an estimated $1.84K.
  • Atea Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #2637 holding.
  • Vanguard Global Advisers first reported a position in Atea Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Global Advisers's Atea Pharmaceuticals position peaked at $138K in Q1 2026.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.